AIM ImmunoTech, Inc. (AIM)
0.2317
0.00 (0.00%)
USD |
NYAM |
Sep 09, 10:53
AIM ImmunoTech Enterprise Value : 0.616M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 0.616M |
| September 04, 2026 | 0.5551M |
| September 03, 2026 | 0.732M |
| September 02, 2026 | 0.7581M |
| September 01, 2026 | 0.7987M |
| August 31, 2026 | 0.5088M |
| August 28, 2026 | 1.448M |
| August 27, 2026 | 1.204M |
| August 26, 2026 | 1.204M |
| August 25, 2026 | 1.320M |
| August 24, 2026 | 1.320M |
| August 21, 2026 | 1.448M |
| August 20, 2026 | 1.294M |
| August 19, 2026 | 0.8624M |
| August 18, 2026 | 0.7378M |
| August 17, 2026 | 1.002M |
| August 14, 2026 | 0.3319M |
| August 13, 2026 | 1.454M |
| August 12, 2026 | 1.408M |
| August 11, 2026 | 1.341M |
| August 10, 2026 | 1.581M |
| August 07, 2026 | 2.231M |
| August 06, 2026 | 1.808M |
| August 05, 2026 | 2.179M |
| August 04, 2026 | 1.581M |
| Date | Value |
|---|---|
| August 03, 2026 | 1.610M |
| July 31, 2026 | 1.309M |
| July 30, 2026 | 0.7697M |
| July 29, 2026 | 0.9146M |
| July 28, 2026 | 0.7987M |
| July 27, 2026 | 1.204M |
| July 24, 2026 | 1.176M |
| July 23, 2026 | 1.204M |
| July 22, 2026 | 1.303M |
| July 21, 2026 | 1.176M |
| July 20, 2026 | 1.204M |
| July 17, 2026 | 1.408M |
| July 16, 2026 | 1.871M |
| July 15, 2026 | 1.436M |
| July 14, 2026 | 1.668M |
| July 13, 2026 | 1.668M |
| July 10, 2026 | 2.161M |
| July 09, 2026 | 2.361M |
| July 08, 2026 | 2.364M |
| July 07, 2026 | 2.814M |
| July 06, 2026 | 2.567M |
| July 02, 2026 | 2.074M |
| July 01, 2026 | 2.538M |
| June 30, 2026 | 2.190M |
| June 29, 2026 | 1.131M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.788M |
| Revenue (Quarterly) | 0.026M |
| Total Expenses (Quarterly) | 3.814M |
| EPS Diluted (Quarterly) | -0.2213 |
| Gross Profit Margin (Quarterly) | -1.95K% |
| Profit Margin (Quarterly) | -14.57K% |
| Earnings Yield | -1.66K% |
| Normalized Earnings Yield | -1573.97 |